What is the value of ‘me-too’ drugs?
Author
Abstract
Suggested Citation
DOI: 10.1007/s10729-013-9225-3
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Marc Fischer & Peter Leeflang & Peter Verhoef, 2010. "Drivers of peak sales for pharmaceutical brands," Quantitative Marketing and Economics (QME), Springer, vol. 8(4), pages 429-460, December.
- Marcel Corstjens & Edouard Demeire & Ira Horowitz, 2005. "New-product success in the pharmaceutical industry: how many bites at the cherry?," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 14(4), pages 319-331.
- Z. John Lu & William S. Comanor, 1998. "Strategic Pricing Of New Pharmaceuticals," The Review of Economics and Statistics, MIT Press, vol. 80(1), pages 108-118, February.
- Gurumurthy Kalyanaram & Glen L. Urban, 1992. "Dynamic Effects of the Order of Entry on Market Share, Trial Penetration, and Repeat Purchases for Frequently Purchased Consumer Goods," Marketing Science, INFORMS, vol. 11(3), pages 235-250.
- Pierre Azoulay, 2002. "Do Pharmaceutical Sales Respond to Scientific Evidence?," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 11(4), pages 551-594, December.
- Prins, R. & Verhoef, P.C., 2007. "Marketing Communication Drivers of Adoption Timing of a New E-Service among Existing Customers," ERIM Report Series Research in Management ERS-2007-018-MKT, Erasmus Research Institute of Management (ERIM), ERIM is the joint research institute of the Rotterdam School of Management, Erasmus University and the Erasmus School of Economics (ESE) at Erasmus University Rotterdam.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Leila Agha & Soomi Kim & Danielle Li, 2020. "Insurance Design and Pharmaceutical Innovation," NBER Working Papers 27563, National Bureau of Economic Research, Inc.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Erik Gronqvist & Douglas Lundin, 2009.
"Incentives for clinical trials,"
Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 18(5), pages 513-531.
- Grönqvist, Erik & Lundin, Douglas, 2006. "Incentives for Clinical Trials," SSE/EFI Working Paper Series in Economics and Finance 636, Stockholm School of Economics.
- Marc Fischer & Peter Leeflang & Peter Verhoef, 2010. "Drivers of peak sales for pharmaceutical brands," Quantitative Marketing and Economics (QME), Springer, vol. 8(4), pages 429-460, December.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
- Brekke, Kurt R. & Kuhn, Michael, 2006.
"Direct to consumer advertising in pharmaceutical markets,"
Journal of Health Economics, Elsevier, vol. 25(1), pages 102-130, January.
- Kurt R Brekke & Michael Kuhn, "undated". "Direct-to-Consumer Advertising in Pharmaceutical Markets," Discussion Papers 03/11, Department of Economics, University of York.
- Kurt R. Brekke & Michael Kuhn, 2005. "Direct to Consumer Advertising in Pharmaceutical Markets," CESifo Working Paper Series 1493, CESifo.
- Brekke, Kurt R. & Kuhn, Michael, 2003. "Direct-to-Consumer Advertising in Pharmaceutical Markets," Working Papers in Economics 05/03, University of Bergen, Department of Economics.
- Anita Rao, 2020. "Strategic Research and Development Investment Decisions in the Pharmaceutical Industry," Marketing Science, INFORMS, vol. 39(3), pages 564-586, May.
- Dranove, David & Garthwaite, Craig & Heard, Christopher & Wu, Bingxiao, 2022.
"The economics of medical procedure innovation,"
Journal of Health Economics, Elsevier, vol. 81(C).
- David Dranove & Craig Garthwaite & Christopher Heard & Bingxiao Wu, 2021. "The Economics of Medical Procedure Innovation," NBER Working Papers 29438, National Bureau of Economic Research, Inc.
- Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
- de Frutos, Maria-Angeles & Ornaghi, Carmine & Siotis, Georges, 2013.
"Competition in the pharmaceutical industry: How do quality differences shape advertising strategies?,"
Journal of Health Economics, Elsevier, vol. 32(1), pages 268-285.
- Siotis, Georges & de Frutos, Maria-Angeles & Ornaghi, Carmine, 2010. "Competition in the Pharmaceutical Industry: How do Quality Differences Shape Advertising Strategies?," CEPR Discussion Papers 8076, C.E.P.R. Discussion Papers.
- Moshe Levy & Adi Rizansky Nir, 2014. "The Pricing of Breakthrough Drugs: Theory and Policy Implications," PLOS ONE, Public Library of Science, vol. 9(11), pages 1-12, November.
- William S. Comanor & Stuart O. Schweitzer, 2007. "Determinants of drug prices and expenditures," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 357-370.
- Joseph DiMasi & Cherie Paquette, 2005. "The economics of follow-on drug research and development: Trends in entry rates and the timing of development — The authors’ reply," PharmacoEconomics, Springer, vol. 23(12), pages 1193-1202, December.
- Dahm, Matthias & González, Paula & Porteiro, Nicolás, 2009.
"Trials, tricks and transparency: How disclosure rules affect clinical knowledge,"
Journal of Health Economics, Elsevier, vol. 28(6), pages 1141-1153, December.
- Matthias Dahm & Paula González & Nicolás Porteiro, 2008. "Trials, Tricks and Transparency: How Disclosure Rules Affect Clinical Knowledge," Working Papers 08.02, Universidad Pablo de Olavide, Department of Economics.
- Dahm, Matthias & González, Paula & Porteiro Fresco, Nicolás, 2008. "Trials, tricks and transparency: how disclosure rules affect clinical knowledge," Working Papers 2072/5360, Universitat Rovira i Virgili, Department of Economics.
- Jie Chen & John Rizzo, 2012. "Pricing dynamics and product quality: the case of antidepressant drugs," Empirical Economics, Springer, vol. 42(1), pages 279-300, February.
- Yaroslav Kryukov, "undated". "Dynamic R&D and the Effectiveness of Policy Intervention in the Pharmaceutical Industry," GSIA Working Papers 2015-E33, Carnegie Mellon University, Tepper School of Business.
- Joseph P Cook, 2014. "Real Option Value and Path Dependence in Oncology Innovation," Seminar Briefing 000077, Office of Health Economics.
- John Cawley & John A. Rizzo, 2005. "The Competitive Effects of Drug Withdrawals," NBER Working Papers 11223, National Bureau of Economic Research, Inc.
- Paolo Pertile & Simona Gamba & Martin Forster, 2018. "Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence," Discussion Papers 18/04, Department of Economics, University of York.
- Susan Brudvig & Michael J. Brusco & J. Dennis Cradit, 2019. "Joint selection of variables and clusters: recovering the underlying structure of marketing data," Journal of Marketing Analytics, Palgrave Macmillan, vol. 7(1), pages 1-12, March.
- Risselada, Hans & Verhoef, Peter C. & Bijmolt, Tammo H.A., 2010. "Staying Power of Churn Prediction Models," Journal of Interactive Marketing, Elsevier, vol. 24(3), pages 198-208.
More about this item
Keywords
Follow-on drugs; Cost savings; Peak share; Share of voice; First-mover advantage; 62J05; 62P20; 90B50;All these keywords.
JEL classification:
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:kap:hcarem:v:16:y:2013:i:4:p:300-313. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.